Estimation of capital requirements for the therapeutics sub-segment of the Canadian biotechnology industry
by Michel Y. Bergeron, Lawrence Kryzanowski, Paul Beaulieu, Sofiene Zorgati
International Journal of Biotechnology (IJBT), Vol. 3, No. 3/4, 2001

Abstract: In this paper, we estimate the capital requirements for the Canadian therapeutics sub-segment of the biotechnology industry using static and dynamic analyses. We estimate the total capital required to develop the current aggregate portfolio of a sample and the population of companies in the therapeutics sub-segment for various growth scenarios in the number of new products entering the aggregate portfolio of products. The findings of this study indicate a large increase in capital requirements, particularly over the next ten years. Although our results potentially can be refined with more precise information, they clearly show the importance of adequate planning on the part of both users and providers of capital if the capital appetite of this sub-segment of the biotechnology industry is to be adequately satisfied in the foreseeable future.

Online publication date: Sun, 13-Jul-2003

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com